Hamlet BioPharma AB (publ)

NGM:HAMLET B Stock Report

Market Cap: SEK 533.5m

Hamlet BioPharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Hamlet BioPharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth45.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Jul 04
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

Mar 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

Nov 10
We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Oct 12
Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Mar 17
Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hamlet BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NGM:HAMLET B - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20240-43-36-36N/A
6/30/2024N/A-42-36-36N/A
3/31/20242-33-39-29N/A
12/31/20232-27-32-22N/A
9/30/20232-24-30-20N/A
6/30/20232-20-30-20N/A
3/31/20230-25-23-23N/A
12/31/20221-24-23-23N/A
9/30/20226-21-23-23N/A
6/30/202210-17-20-20N/A
3/31/202213-10-13-13N/A
12/31/202113-8-11-11N/A
9/30/202110-8-10-10N/A
6/30/20219-8-6-6N/A
3/31/20216-13-15-15N/A
12/31/20205-17-15-15N/A
9/30/20203-23-18-18N/A
6/30/20200-23-23-23N/A
3/31/20200-24-21-21N/A
12/31/2019N/A-22-21-21N/A
9/30/2019N/A-17-18-18N/A
6/30/2019N/A-17-15-15N/A
3/31/2019N/A-14-14-14N/A
12/31/2018N/A-15-15-15N/A
9/30/2018N/A-15-16-15N/A
6/30/2018N/A-16N/A-16N/A
3/31/2018N/A-15N/A-15N/A
12/31/2017N/A-17N/A-14N/A
9/30/2017N/A-16N/A-13N/A
6/30/2017N/A-14N/A-10N/A
3/31/2017N/A-13N/A-9N/A
12/31/2016N/A-7N/A-8N/A
9/30/2016N/A-6N/A17N/A
6/30/2016N/A-5N/A-6N/A
3/31/2016N/A-4N/A-4N/A
12/31/2015N/A-3N/A-3N/A
9/30/2015N/A-1N/A-24N/A
6/30/2015N/A-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if HAMLET B's forecast earnings growth is above the savings rate (1.2%).

Earnings vs Market: Insufficient data to determine if HAMLET B's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if HAMLET B's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if HAMLET B's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if HAMLET B's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HAMLET B's Return on Equity is forecast to be high in 3 years time


Discover growth companies